Sarah S Welsh1, Nan Lin2, Alexis A Topjian1, Nicholas S Abend3. 1. Division of Critical Care Medicine, Children's Hospital of Philadelphia, Department of Anesthesia and Critical Care Medicine, The University of Pennsylvania, United States. 2. Division of Neurology, Children's Hospital of Philadelphia, Departments of Neurology and Pediatrics, The University of Pennsylvania, United States. 3. Division of Neurology, Children's Hospital of Philadelphia, Departments of Neurology and Pediatrics, The University of Pennsylvania, United States. Electronic address: abend@email.chop.edu.
Abstract
PURPOSE: Acute seizures are common in critically ill children. These patients would benefit from intravenous anti-seizure medications with few adverse effects. We reviewed the usage and effects of intravenous lacosamide in critically ill children with seizures or status epilepticus. METHODS: This retrospective series included consecutive patients who received at least one dose of intravenous lacosamide from April 2011 to February 2016 in the pediatric intensive care unit of a quaternary care children's hospital, including patients with new lacosamide initiation and continuation of outpatient oral lacosamide. Dosing and prescribing practices were reviewed. Adverse effects were defined by predefined criteria, and most were evaluated during the full admission. RESULTS: We identified 51 intensive care unit admissions (47 unique patients) with intravenous lacosamide administration. Lacosamide was utilized as a third or fourth-line anti-seizure medication for acute seizures or status epilepticus in the lacosamide-naïve cohort. One patient experienced bradycardia and one patient experienced a rash that were considered potentially related to lacosamide. No other adverse effects were identified, including no evidence of PR interval prolongation. CONCLUSIONS: Lacosamide was well tolerated in critically ill children. Further study is warranted to evaluate the effectiveness of earlier lacosamide use for pediatric status epilepticus and acute seizures.
PURPOSE: Acute seizures are common in critically illchildren. These patients would benefit from intravenous anti-seizure medications with few adverse effects. We reviewed the usage and effects of intravenous lacosamide in critically illchildren with seizures or status epilepticus. METHODS: This retrospective series included consecutive patients who received at least one dose of intravenous lacosamide from April 2011 to February 2016 in the pediatric intensive care unit of a quaternary care children's hospital, including patients with new lacosamide initiation and continuation of outpatient oral lacosamide. Dosing and prescribing practices were reviewed. Adverse effects were defined by predefined criteria, and most were evaluated during the full admission. RESULTS: We identified 51 intensive care unit admissions (47 unique patients) with intravenous lacosamide administration. Lacosamide was utilized as a third or fourth-line anti-seizure medication for acute seizures or status epilepticus in the lacosamide-naïve cohort. One patient experienced bradycardia and one patient experienced a rash that were considered potentially related to lacosamide. No other adverse effects were identified, including no evidence of PR interval prolongation. CONCLUSIONS:Lacosamide was well tolerated in critically illchildren. Further study is warranted to evaluate the effectiveness of earlier lacosamide use for pediatric status epilepticus and acute seizures.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Estevo Santamarina; Manuel Toledo; Maria Sueiras; Miquel Raspall; Nadim Ailouti; Elena Lainez; Isabel Porta; R De Gracia; Manuel Quintana; Javier Alvarez-Sabín; Xavier Salas Puig Xavier Salas Puig Journal: J Neurol Date: 2013-12 Impact factor: 4.849
Authors: Laura M F F Guilhoto; Tobias Loddenkemper; Vasu D Gooty; Alexander Rotenberg; Masanori Takeoka; Frank H Duffy; David Coulter; David Urion; Blaise F Bourgeois; Sanjeev V Kothare Journal: Pediatr Neurol Date: 2011-06 Impact factor: 3.372
Authors: Giuseppe d'Orsi; Maria Grazia Pascarella; Tommaso Martino; Elena Carapelle; Francesca Pacillo; Maria Teresa Di Claudio; Daniela Mancini; Marina Trivisano; Carlo Avolio; Luigi M Specchio Journal: Seizure Date: 2016-09-22 Impact factor: 3.184
Authors: J Miró; M Toledo; E Santamarina; A C Ricciardi; V Villanueva; A Pato; J Ruiz; R Juvany; M Falip Journal: Seizure Date: 2012-11-03 Impact factor: 3.184
Authors: Michael J Bell; Jessica Carpenter; Alicia K Au; Robert F Keating; John S Myseros; Amanda Yaun; Steven Weinstein Journal: Neurocrit Care Date: 2009 Impact factor: 3.210